MAPT and Alzheimer disease: Identification of BBB leak and possibly concomitant glymphatic flow dysfunction in preclinical AD (preceding accumulation of either Aβ or Hp-tau), requires use of reliable non-invasive tools to monitor results of future treatment strategies aimed at “stopping the leak” and “clearing the drain.” The MRI tools discussed above could serve this role.